#United States #San Francisco #TileDB #Kepler AI #Tahoe Therapeutics

A Groundbreaking Partnership: TileDB, Kepler AI, and Tahoe Therapeutics

In an exciting development in computational biology, TileDB, Inc., Kepler AI, and Tahoe Therapeutics have formed a strategic partnership aimed at transforming single-cell data analysis. This collaboration has resulted in the launch of a novel public platform, enabling researchers to conduct sophisticated AI agent-based queries on extensive single-cell datasets with unmatched scalability.

The Need for Advanced Analysis

As the field of single-cell genomics continues to expand at an unprecedented pace, the associated datasets grow larger and more complex. Researchers frequently find it challenging to query these vast amounts of data effectively, especially using traditional file formats like h5ad. Recognizing this challenge, TileDB brings forth its unique multimodal database technology, designed specifically to handle such multidimensional data seamlessly.

TileDB's Innovative Approach

TileDB's multimodal database offers a robust solution that can manage the diverse complexities presented in single-cell genomics. By housing the Tahoe-100M Atlas—a dataset containing over 100 million transcriptomic profiles from 50 different cancer cell lines exposed to numerous small-molecule perturbations—this new platform stands to empower pharmaceutical and biotech teams. The Tahoe-100M atlas, generated utilizing Mosaic technology, is an innovative resource made accessible to facilitate advanced research.

Unleashing AI Potential

Previously, due to the limitations posed by large datasets like Tahoe-100M, Kepler AI could only develop agents using pseudo-bulk data, which significantly restricted analytical capabilities. This partnership changes the game by allowing AI agents to interact directly with full-resolution single-cell data. This means researchers are now privy to the intricate details of cellular behaviors that were previously obscured in bulk data analysis.

The new platform makes available roughly 250 gigabytes of data optimally tailored for AI-driven analysis, enabling faster and more insightful discoveries. Some key functionalities of this platform include:

• - Real-time AI agent queries on multidimensional single-cell datasets
• - Scalable analysis from individual cells to insights at population levels
• - Capabilities to uncover biomarkers and therapeutic pathways hidden in bulk data

Remarks from Industry Leaders

Stavros Papadopoulos from TileDB expressed excitement about this innovative endeavor, stating, “TileDB is the only database technology capable of handling the multidimensional nature of single-cell genomics data while maintaining the performance necessary for real-time AI agent queries.”

Ashton Teng, CEO of Kepler AI, also shared profound insights about the collaboration, adding, “This partnership represents a paradigm shift in how we approach single-cell analysis.” Kepler AI, known for its state-of-the-art AI-native data interfaces, complements this initiative by allowing for automated, end-to-end bioinformatics workflows.

Access to the Platform

The platform is publicly accessible, and users can register at Tahoe Bio to select the novel single-cell dataset for analysis. Importantly, a free version of the Kepler AI platform is available, albeit with a limit of 32GB of memory—meaning that a representative subset of cells will be selected for analysis. Additional information about custom compute resources can be sought through direct contact with the respective companies.

Equipped with this pioneering platform, researchers can look forward to thoroughly understanding cellular responses and dynamics. They will be able to:

• - Identify transcriptional correlates for drug susceptibility and resistance
• - Analyze cell cycle state dynamics influenced by various drug classes
• - Characterize specific transcriptional responses tied to targeted therapies

In conclusion, this partnership between TileDB, Kepler AI, and Tahoe Therapeutics marks a significant milestone in the realm of biological data analysis. It is ushering in new possibilities that could accelerate drug discovery and foster groundbreaking scientific advancements. By democratizing access to comprehensive single-cell datasets, the three companies are poised to significantly contribute to the progression of life sciences.